Figure 9.

Inhibition of breast cancer metastasis in bone by proteasome inhibitor. Mice were injected intracardially with 1 × 10⁵ MDA-MB-231-GFP cells. The mice were then treated with Bortezomib and BU-32 using a dose of 0.06 mg/kg body weight or with vehicle PBS as control. Whole-body high-resolution fluorescence images of MDA-MB231-GFP-expressing breast cancer metastatic cells in the skeleton of live intact animals were measured after 5 weeks. Representative fluorescence images are shown for (a) the control group, (b) Bortezomib-treated mice and (c) BU-32-treated mice. (d) The fluorescence intensities were quantified. GFP, green fluorescent protein; i.c., intracisternal.